---------- Forwarded message ----------
From: U.S. Food & Drug Administration (FDA) <fda@service.govdelivery.com>
Date: Tue, Jul 1, 2014 at 9:33 AM
Subject: Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter
To: iammejtm@gmail.com
. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.
From: U.S. Food & Drug Administration (FDA) <fda@service.govdelivery.com>
Date: Tue, Jul 1, 2014 at 9:33 AM
Subject: Bristol-Myers Squibb Issues Voluntary Nationwide Recall of COUMADIN (Warfarin Sodium) for Injection Due to Presence of Particulate Matter
To: iammejtm@gmail.com
You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).
This information has recently been updated and is now available.
07/01/2014 11:34 AM EDT
Bristol-Myers Squibb Company (NYSE:BMY) is voluntarily recalling six lots of COUMADIN FOR INJECTION, 5 mg single-use vials in the U.S. This recall is a precautionary measure based on the company's investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples.
Manage your FDA Subscriptions:
- Update your preferences or unsubscribe
- Questions about this service? Please visit subscriberhelp.govdelivery.com
- Other inquiries? webmail@oc.fda.gov
| This email was sent to iammejtm@gmail.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
Jeremy Tobias Matthews
No comments:
Post a Comment